CM
PTX

Castleark Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Castleark Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-51,568
Closed -$5.51M – 414
2015
Q1 		$5.51M Sell
51,568
-20,703
-29% -$1.97M 0.13% 181
2014
Q4 		$6.79M Buy
+72,271
New +$6.89M 0.17% 149

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Castleark Management's PTX Position: Q2 2015 in Review

Castleark Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2015, closing a stake of 51,568 shares — an estimated $5.51M sold.

Castleark Management first reported a position in PTX in Q4 2014 and held it in 2 quarters. The position peaked at $6.79M in Q4 2014. 114 funds tracked by Wall St. Rank hold PTX as of Q2 2015.

  • Castleark Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2015 after selling out during the quarter.
  • Castleark Management sold 51,568 Pernix Therapeutics Holdings, Inc. shares in Q2 2015, an estimated $5.51M.
  • Castleark Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2014 and held it in 2 quarters.
  • Castleark Management's Pernix Therapeutics Holdings, Inc. position peaked at $6.79M in Q4 2014.
  • 114 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2015.

Based on Castleark Management's 13F filing for Q2 2015, filed 17 Aug 2015.